Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in CD19+ MPAL
NCT06876701Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in mixed phenotype acute leukemia (MPAL), sponsored by Ruijin Hospital. Primary endpoint: Negative conversion rate of evaluable residual lesions (MRD) at 1 year. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT06876701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876701.